title: High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.
abstract: Few antimicrobials are currently active to treat infections caused by extremely resistant Gram-negative bacilli (ERGNB), which represent a serious global public health concern. Tigecycline, which covers the majority of these ERGNB (with the exception of Pseudomonas aeruginosa), is not currently approved for hospital-acquired pneumonia, and several meta-analyses have suggested an increased risk of death in patients receiving this antibiotic. Other studies suggest that the use of high-dose tigecycline may represent an alternative in daily practice. De Pascale and colleagues report that the clinical cure rate in patients with ventilator-associated pneumonia is significantly higher with a high dose of tigecycline than with the conventional dose, although mortality was unaffected. This high dose is safe; no patients required discontinuation or dose reduction.
authors.forename: José
authors.initials: J
authors.lastname: Garnacho-Montero
authors.forename: Carmen
authors.initials: C
authors.lastname: Ferrándiz-Millón
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016638:Critical Illness / Q000628:therapy*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008911:Minocycline / Q000031:analogs & derivatives*; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D008911:Minocycline